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Both osteoclast-activating factor (OAF) and prostaglandins are potent local media- 
tors of bone resorption  (1-3).  Both of these factors are produced by cells involved in 
immune responses and are potential mediators of the bone destruction associated with 
diseases  such  as  rheumatoid  arthritis,  periodontal  disease,  and  cholesteatoma  (4). 
They may also be produced at the site of metastatic bone lesions. Their interactions 
at  bone resorbing sites  therefore  may be important  in  the bone resorption  which is 
associated  with  a  variety  of inflammatory  and  neoplastic  diseases.  To  test  if OAF 
production is dependent on prostaglandins, we have examined the effects of a number 
of structurally unrelated  inhibitors of prostaglandin synthetase on the production of 
OAF  by phytohemagglutinin-(PHA)  activated  human  peripheral  blood  leukocytes. 
The production of OAF was inhibited  by indomethacin,  R020-5720 and flufenamic 
acid.  Inhibition  of OAF production  by these agents was reversed by adding prosta- 
glandins of the E  series back to the leukocyte suspension.  These results indicate that 
prostaglandin synthesis is necessary for OAF production. 
Materials  and Methods 
Peripheral  blood  leukocytes were  obtained  from  plateletpheresis  donations  from normal 
volunteers at the Connecticut Red Cross in Farmington, Conn. 5 ml of 5% dextran was added 
to  the  plasma-leukocyte-red  mixture  and  the  leukocyte huffy coat  was separated  from  the 
sedimented erythrocytes. Leukocytes were cultured at a concentration of 1 ×  10  s cells/ml in 
BGJ medium (5) (Grand Island Biological Co., Grand Island, N. Y., formula 78-0088) without 
added serum.  PHA-M  1%  (Grand Island Biological Co.) was used to stimulate the leukocyte 
cultures. The leukocytes were cultured  for 24-72 h. At the end of the culture, the supernates 
were removed by gentle aspiration and frozen at -20°C until OAF assay. After the supernates 
were removed, the leukocytes were pulsed  with  [aH]thymidine or all-amino acids for 4-6 h 
according to the methods previously described  (5). The inhibitors of prostaglandin synthesis 
which were used were indomethacin, d,-l-6-choromethyi-carbazole-2-acetic acid (R020-5720) 
(Hoffman-LaRoche,  Inc.,  Nutley,  N.  J.)  and  flufenamic  acid  (Aldrich  Chemical  Co., 
Metuchen, N. Y.).  Each of these structurally unrelated drugs inhibits prostaglandin synthesis 
at these concentrations (6-8). These agents were added to the leukocyte culture suspensions 2 
h before activation of the leukocytes with PHA. 
Bone resorbing activity was assayed in the leukocyte supernates by methods similar to those 
which have been previously described (5, 9). Pregnant mice at the 16th-day of gestation were 
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TABLE  I 
Effects of Prostaglandin Synthetase Inhibitors on [3H]Thyrnidine ([aH]TdR) and 3H-Amino Acid 
(3H-AA ) Incorporation and OAF Production by Leukocytes 
OAF production 
PHA  Inhibitors (10  -8 M)  [SH]TdR  incorpora-  aH-AA incorpo-  (treated/control 
tion  ration  ratios of 45Ca re- 
lease) 
Exp.  1 
Exp. 2 
Exp. 3 
1%  cpm  cpm 
+  --  3,094  :t: 411"  4,699  ±  744*  1.72:1: 0.13" 
+  Indomethacin  2,928  ±  133"  3,501  ±  468*  1.05 :t: 0.125 
-  --  1,125  ±  48  1,111  ±  91  1.10 ±  0.11 
-  Indomethacin  1,222 ±  30  974  ±  25  0.80  ±  0.06 
+  --  38,564  ±  2604*  4,008  ±  211"  1.95 zt: 0.17" 
+  R020-5720  24,374  ±  2407*  6,063  ±  245*  1.00 ±  0.04:1: 
-  --  1,254 ±  43  1,053 ±  11  1.13 ±  0.12 
-  R020-5720  1,185:1:123  1,651  ±  28  1.18 +  0. t6 
+  --  4,410  :t: 263*  6,862  ±  447*  1.76 ±  0.06* 
+  Flufenamic acid  6,708  ±  332*  6,809  ±  417"  1.00 ±  0.055 
--  --  1,410 ±  84  2,001  +  130  0.98  +  0.03 
--  Flufenamic acid  1,307 ±  52  1,855 ±  53  0.90  ±  0.03 
The inhibitors were added to the leukocyte cultures 2 h before PHA. The leukocytes were then cultured 
for 48 h. Values for [aH]TdR and aH-AA incorporation are means ±  standard errors for three leukocyte 
cultures. Values for OAF production are means ±  standard errors for four bone cultures. 
* Significantly greater than corresponding control, P <  0.05. 
$ Significantly different from stimulated cultures without inhibitor, P <  0.05. 
injected subcutaneously with 0.05 mCi of 45Ca. The next day the fetuses were removed and the 
mineralized shafts of the radii  and  ulnae were dissected  free from surrounding  subcutaneous 
soft tissue and  the cartilagenous ends.  The bones were cultured  in control  media for 24 h  to 
allow for exchange of loosely complexed 45Ca with stable calcium in the medium. The bones 
were then cultured with the leukocyte culture supernates  for 72 h  and bone resorbing activity 
was  assessed  as  the  percent  of total  radioactivity  released  from  the  bones  into  the  culture 
medium during the period of culture.  The leukocyte culture supernates  were diluted  1:1  with 
fresh medium before assay for bone resorbing activity. Bone resorbing activity was also expressed 
as ratios of~Ca release from the test bones compared with corresponding paired bones cultured 
in control media. Four bones were used in each test group and differences were assessed using 
Student's t test. 
Results  and  Discussion 
Each of the structurally  unrelated  inhibitors  of prostaglandin  synthetase  inhibited 
the production  of OAF  by leukocytes at  10  -5 M  (Table I).  In  the same experiments, 
these drugs  did not  inhibit  protein  or DNA  synthesis  by  the leukocytes as measured 
by the incorporation of all-amino acids of [aH]thymidine into the cells. The inhibitory 
effects of these drugs on OAF  production were obtained with concentrations as low as 
10  -7 M  (data  not  shown).  Although  each  of these  drugs  inhibited  OAF  production, 
they  had  no  effect  on  the  biological activity due  to  OAF  when  they  were  added  to 
OAF  containing media in concentrations of 10 -5 M. OAF  production was restored by 
adding  prostaglandins  of the  E  series  together  with  indomethacin  to  the  leukocytes 
before the  leukocytes were  activated  with  PHA  (Table  II).  Similar effects were seen 
with  both  prostaglandin-E1  and  prostaglandin-E2.  However, prostaglandin-Fl~  and 
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TABLE II 
Restoration of Leukocyte Production of OAF by Addition of Prostaglandin E1 (PGE1) to the Cultures 
Treated with Indomethacin ( Indo), an Inhibitor of Prostaglandins Synthesis 
Source of media applied to bone cultures 
Bone resorbing activity (treated/control ratios) 
Before diafihration  After diafihration 
Indo,  PGEI,  PGEj,  PHA-act lk 
10  -n M  10  -8 M  10  -1 M 
-  -  -  +  1.82 ±  0.37*  1.54 +  0.08* 
+  --  --  +  0.89 ±  0.02  1.13 ±  0.05 
+  +  --  +  2.47 ±  0.43*  1.75 :l: 0.06* 
+  --  +  +  1.84 .± 0.41"  1.68 ±  0.09* 
-  +  --  --  2.81 ±  0.48*  0.99 ±  0.02 
-  --  +  --  1.97 ±  0.02*  1.06 ±  0.03 
The prostaglandins and indo were added to the leukocytes 2 h before the addition of PHA. The leukocytes 
(lk) were then cultured for 48 h. The Ik culture supernates were assayed for bone resorping activity before 
and after diafihration to remove the prostaglandins. 
Values are means  ±  SEM for four pairs of bone cultures. 
* Significantly greater than 1.0, P < 0.05. 
removed  from  the  leukocyte-conditioned  media  before  assay  for  bone  resorbing 
activity by diafiltration (uhrafiltration with  continuous  replacement  of the  filtered 
volume with  10 vol of fresh media) across an Amicon UM2 membrane (Amicon Corp., 
Lexington, Mass.), which has a  nominal tool wt cut-off of 1,000 daltons. Restoration 
of OAF production indicates that prostaglandin synthesis by the leukocyte cultures is 
necessary for OAF to be produced. 
A  number  of  studies  have  indicated  that  prostaglandins  may  be  endogenous 
modulators of cell-mediated immune responses and lymphokine production.  Prosta- 
glandins have been shown  to both stimulate and  inhibit the production of different 
lymphokines. Most of the described effects of prostaglandins on lymphokine produc- 
tion have been inhibitory. Large concentrations of prostaglandins have been  shown 
to inhibit macrophage migration inhibition factor production by guinea pigs (10,  1 1), 
mitogen-induced  stimulation  of  murine  lymphocytes  (12)  and  human  leukocyte 
inhibitory factor production  (13). Goodwin et al. have suggested that  prostaglandin 
production by glass-adherent cells inhibits T-cell mitogenesis (14).  In contrast, pros- 
taglandins of the  E  series appear to  be necessary for the  production of a  factor  by 
activated leukocytes which increases vascular permeability (15). Now we have shown 
that  prostaglandins  are  also  necessary  for  the  production  of another  lymphokine, 
OAF. 
The cell source of prostaglandins necessary for OAF production in our experiments 
is likely to be the monocyte.  The  monocyte is the principal PGE-producing cell in 
human peripheral blood (16). The presence of monocytes in the leukocyte population 
is necessary for OAF production, but not for leukocyte activation (17). Nonadherent 
lymphocytes devoid of monocytes which  are incubated  with  PHA  synthesize DNA 
and  protein,  but  do  not  release  OAF  (17).  T  cells  alone  require  the  presence  of 
monocytes in order to release OAF after activation with PHA (18). Our data reported 
here  suggests  that  the  synergy  between  the  monocyte  and  the  lymphocyte in  the 
production of OAF may be mediated by prostaglandins. 
Regardless of the  mechanism  of the interaction  between  prostaglandins and  leu- 
kocytes in OAF  production, our data indicate that  prostaglandins are necessary for 282  YONEDA ET AL.  BRIEF  DEFINITIVE REPORT 
the  production  of OAF  by  stimulated  leukocytes,  but  they  are  not  essential  for 
leukocyte activation as assessed by DNA or protein synthesis. These data also clearly 
show that responses to indomethacin and related drugs do not prove a prostaglandin- 
mediated mechanism of bone resorption in animals or in patients with hypercalcemia. 
Summary 
The production of osteoclast-activating factor (OAF) by normal human peripheral 
blood  leukocytes  stimulated  by  phytohemagglutinin was  inhibited  by  a  series  of 
structurally  unrelated  inhibitors  of  prostaglandin  synthetase.  Inhibition  of  OAF 
production by these agents was reversed by adding prostaglandins of the E series back 
to  the  leukocyte suspension.  These  results  indicate  that  prostaglandin  synthesis  is 
necessary for OAF production. 
Received  for publication 24 October 1978. 
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